Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | PDE2A | O00408 | 2/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | AHCY | P23526 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429134 | 1.00 | ADORA2A (0.56) | ADORA2AADORA3PDE2AHSPA5AHCY | |
| SCHEMBL14429149 | 0.90 | ADORA3 (0.49) | ADORA2AADORA3PDE2AADORA1 | |
| SCHEMBL18671451 | 0.84 | AHCY (0.49) | ADORA2AADORA3PDE2AHSPA5AHCY | |
| SCHEMBL11427985 | 0.83 | PDE2A (0.64) | ADORA2AADORA3PDE2AHSPA5AHCY | |
| SCHEMBL5961364 | 0.83 | PDE2A (0.64) | ADORA2AADORA3PDE2AHSPA5AHCY | |
| SCHEMBL14429135 | 0.83 | ADORA2A (0.68) | ADORA2AADORA3AHCYADORA1DOT1L | |
| SCHEMBL14440591 | 0.81 | ADORA2A (0.55) | ADORA2AADORA3AHCYADORA1 | |
| SCHEMBL14440593 | 0.81 | ADORA2A (0.55) | ADORA2AADORA3AHCYADORA1 | |
| SCHEMBL14428965 | 0.81 | PDE2A (0.59) | ADORA2AADORA3PDE2AHSPA5AHCY | |
| SCHEMBL14429057 | 0.81 | PDE2A (0.59) | ADORA3PDE2AHSPA5AHCYADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | ADORA2A 566/4885ADORA3 332/4885PDE2A 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.